RT Book, Section
A1 Connes, Philippe
A1 Hyacinth, Hyacinth I.
A1 Naik, Rakhi P.
A2 Gladwin, Mark T.
A2 Kato, Gregory J.
A2 Novelli, Enrico M.
SR Print(0)
ID 1179344404
T1 Sickle Cell Trait
T2 Sickle Cell Disease
YR 2021
FD 2021
PB McGraw-Hill Education
PP New York, NY
SN 9781260458596
LK hemonc.mhmedical.com/content.aspx?aid=1179344404
RD 2024/04/24
AB Sickle  cell  trait  (SCT),  defined  as  the  heterozygous  inheritance  of  sickle  hemoglobin  (HbS),  is  one  of  the  most  common  hemoglobin  mutations  in  the  world.  Prevalence  estimates  suggest  that  SCT  is  found  in  approximately  300  million  individuals  worldwide  and  nearly  3  million  individuals  in  the  United  States.  The  rates  of  SCT  are  highest  among  populations  living  in  sub-Saharan  Africa  and  parts  of  the  Mediterranean,  the  Middle  East,  and  India,  as  well  as  among  individuals  whose  ancestors  come  from  these  areas,  such  as  people  of  African  descent  living  in  Europe  or  the  Americas.  Prevalence  of  SCT  ranges  from  7%  to  9%  in  the  African  American  population  in  the  United  States,  and  rates  may  exceed  25%  in  regions  of  malarial  endemicity  such  as  Nigeria  and  tribal  India.1  Evidence  of  the  evolutionary  advantage  of  SCT  in  conferring  protection  against  severe  malaria  is  profound  and  undisputed.  Consistent  studies  have  demonstrated  a  90%  risk  reduction  of  severe  and  cerebral  malaria  among  SCT  carriers.1